Schedule 13G ownership disclosure
Tenax Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 88032L605
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 423,415.00 · Class: 6.8%
- Point72 Capital Advisors, Inc.
Shares: 423,415.00 · Class: 6.8%
- Steven A. Cohen
Shares: 423,415.00 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-26-001129
- Form type
- SCHEDULE 13G/A
- Filer
- Point72 Asset Management, L.P.
- CIK
- CIK 1603466
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership